Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics reported positive topline induction data from Part A of the Phase 2 SKYLINE trial for SPY001, achieving the primary endpoint with a 9.2-point reduction in RHI score. The company strengthened its balance sheet with $463 million in gross proceeds from a recent offering, bringing pro forma cash to $1.2 billion with a runway into the second half of 2029.
Key figures
- Net loss
- 69005000
- Cash runway
- into second half of 2029
- Ga expenses
- 15230000
- Rd expenses
- 60411000
- Cash position
- 741500000
- Shares outstanding
- 78839858
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.